Search

Senad Divanovic

from Cincinnati, OH
Age ~47
Get Report
Also known as:
Senad Rank, Senad C
Phone and address:
8562 Northport Dr, Cincinnati, OH 45255
(513) 631-3754
Related to:
Robert H Southard, 67Mark E Crawn, 45Nahida Divanovic, 81John R Bratt, 54Georgia D RankAllison A Divanovic, 48Sanida D Bratt, 51Bradley M Rank, 47Nahida DivanovicMichael P Rank, 77Phyllis A Rank, 77
Connected to:
Karla DivasGeoffrey J Dive, 64Dave A Divecha, 61Pravin DivekarThomas A Divel, 66Kassandra L Divelbiss, 54Jenny L Diveley, 39William J Diveley, 52Paula J Divello, 52Cathy C Dively, 65

Senad Divanovic Phones & Addresses

  • 8562 Northport Dr, Anderson, OH 45255 (513) 631-3754
  • Cincinnati, OH
  • 623 7Th Ave, Stillwater, OK 74074
  • Tulsa, OK
  • Lake Bluff, IL
  • Greencastle, IN

Work

Company: Cincinnati childrens hospital medical center Sep 2012 Position: Assistant professor

Education

Degree: Ph.D. School / High School: University of Cincinnati College of Medicine 2000 to 2005 Specialities: Molecular and Developmental Biology

Industries

Research

Resumes

Resumes

Senad Divanovic Photo 1

Associate Professor

View page
Location:
Cincinnati, OH
Industry:
Research
Work:
Cincinnati Childrens Hospital Medical Center since Sep 2012
Assistant Professor
Education:
University of Cincinnati College of Medicine 2000 - 2005
Ph.D., Molecular and Developmental Biology Oklahoma State University 1998 - 2000
M.S., Microbiology and Molecular and Cellular Biology DePauw University 1994 - 1998
BA, Biology and German

Publications

Us Patents

Methods And Compositions For The Modulation Of Immune Responses And Autoimmune Diseases

View page
US Patent:
20080260751, Oct 23, 2008
Filed:
Apr 14, 2005
Appl. No.:
10/599797
Inventors:
Christopher L. Karp - Cincinnati OH, US
Senad Divanovic - Cincinnati OH, US
International Classification:
A61K 39/395
A61K 31/7088
A61K 38/17
A61P 37/06
G01N 33/53
US Classification:
4241581, 514 44, 514 12, 435 78
Abstract:
The present invention relates to a regulation of inflammation and immune responses. The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an activator of RP105. The condition is typically associated with TLR-4 activation and cytokine production. Conditions addressed by the invention include sepsis, septic shock, inflammation, rheumatoid arthritis and Crohn's disease. The invention also provides the use of an activator of RP105 in the manufacture of a medicament for use in the treatment of a condition associated with cytokine production and methods for identifying an activator of RP105, which is also suitable for use in the treatment of a condition associated with stimulus-induced cytokine production. More specifically the patent relates to the use of RP105 as a specific inhibitor of TLR4 signaling and as a physiological regulator of TLR4 signaling for the treatment of TLR4-mediated inflammation and immune-related diseases. This invention also relates to treating a subject having a disease or condition associated with Toll-like receptor 4.

Methods For The Modulation Of Leishmania Major Infection In Mammals

View page
US Patent:
20100261774, Oct 14, 2010
Filed:
Feb 16, 2010
Appl. No.:
12/658895
Inventors:
Christopher L. Karp - Cincinnati OH, US
Senad Divanovic - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 31/405
A61P 33/02
US Classification:
514419
Abstract:
Embodiments of the invention include methods for treating an infection of a mammal by an organism, such as by administering an effective amount of an inhibitor of indolamine 2,3-dexygenase (IDO). A preferred inhibitor is 1-methyl-tryptophan (1MT). The treatment can be highly beneficial as a treatment for visceral leishmaniasis.

Methods Of Treatment And Prevention Of Diet-Induced Obesity And Sequelae Thereof

View page
US Patent:
20110200580, Aug 18, 2011
Filed:
Aug 11, 2008
Appl. No.:
12/672869
Inventors:
Christopher L. Karp - Cincinnati OH, US
Stuart P. Weisberg - New York NY, US
Senad Divanovic - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 39/395
A61K 38/00
A61K 31/7105
G01N 33/53
A61P 3/04
US Classification:
4241301, 514 48, 514 44 A, 435 721
Abstract:
Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopeptide ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound

Regulation Of Energy Metabolism And Obesity By Modulating B Cell Activating Factor (Baff, Blys) Or Baff Signaling

View page
US Patent:
20120264680, Oct 18, 2012
Filed:
Feb 2, 2012
Appl. No.:
13/364776
Inventors:
Christopher L. Karp - Seattle WA, US
Senad Divanovic - Cincinnati OH, US
Jessica L. Allen - Saxapahaw NC, US
Assignee:
CHILDREN'S HOSPITAL MEDICAL CENTER - Cincinnati OH
International Classification:
A61K 38/19
A61K 31/715
A61P 3/04
A61K 31/7088
US Classification:
514 48, 514 44 R, 514 54
Abstract:
Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors.

Regulation Of Energy Metabolism And Obesity By Modulating A Proliferation-Inducing Ligand (April) Or April Signaling

View page
US Patent:
20140221279, Aug 7, 2014
Filed:
Apr 14, 2014
Appl. No.:
14/252498
Inventors:
- Cincinnati OH, US
Senad Divanovic - Cincinnati OH, US
Jessica L. Allen - Saxapahaw NC, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 38/19
US Classification:
514 48
Abstract:
Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors.

Regulation Of Energy Metabolism And Obesity By Modulating B Cell Activating Factor (Baff, Blys) Or Baff Signaling

View page
US Patent:
20140170107, Jun 19, 2014
Filed:
Feb 12, 2014
Appl. No.:
14/179183
Inventors:
- Cincinnati OH, US
Senad Divanovic - Cincinnati OH, US
Jessica L. Allen - Saxapahaw NC, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 38/19
A61K 31/739
US Classification:
424 851, 514 48, 514 44 R, 514 54
Abstract:
Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors.
Control profile
Senad Divanovic from Cincinnati, OH, age ~47 Get Report